-
Expert Recommendations on the Clinical and Cost Effectiveness of Hexvix® blue-light cystoscopy published in European UrologyOslo, Norway, 10th July 2014: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to note that updated expert recommendations on the clinical and cost effectiveness of Hexvix have been published in European Urology.10 Jul 2014 -
FOCUS ON ACNEThe Swedish Medical Product Agency (MPA) together with The Public Health Authorities with updated recommendations for acne treatment.01 Jul 2014
-
US Congressman Tom Reed Introduces Bill To Give Cancer Patients Access To Breakthrough TreatmentBill makes most up-to-date cancer treatment available to patients; requires fair payment policy for hospitals25 Jun 2014
-
GlobalData June 17th: Novel product launches to reinvigorate acne treatment by 2018New Market Opportunity Analysis and forecast to 2018 prepared by GlobalData highlights Visonac photodynamic therapy for acne as one of the anticipated new product launches that will drive the expansion within the acne market.23 Jun 2014
-
Progress in Patient Access to CysviewBladder Cancer Advocacy Network urging Congress to enact legislation to secure access to Blue Light Cystoscopy with Cysview19 Jun 2014
-
FOCUS ON CERVICAL CANCERGerman Institute for Quality and Efficacy in Health Care (IQWiG) confirms benefit of human papilloma-virus (HPV) testing for preventing cervical cancer.17 Jun 2014
-
Results for the first quarter 2014Oslo, Norway, 7 May 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the first quarter 2014.07 May 2014
-
FOCUS ON CERVICAL CANCERFDA approves first HPV test for primary cervical cancer screening28 Apr 2014
-
Focus on cervical cancerFDA advisory committee recommends Roche's HPV test for primary screening of cervical cancer.17 Mar 2014
-
Results for the fourth quarter and full year 2013Oslo, Norway, 27 February 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the fourth quarter and full year of 2013.27 Feb 2014
-
Regulatory Update on Cevira<sup>®</sup>27 Dec 2013
-
Photocure provides update on Visonac<sup>®</sup>Novel treatment for moderate to severe acne30 Oct 2013
-
Results for the third quarter and the first nine months 2013Oslo, Norway, 23 October 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the third quarter and first nine months of 2013.23 Oct 2013
-
Photocure Sponsors symposium at the 29th Congress of the Scandinavian Association of Urology and Urological NursesDiagnosis and management of non-muscle invasive bladder cancer: How to reach excellence!30 Sep 2013
-
Cevira® Phase 2b results presented at the annual Colposcopy meeting in Cologne, Germany22. Jahrestagung der Arbeitsgemeinschaft für Zervixpathologie und Kolposkopie, 26.-28. September 201330 Sep 2013
-
Results for the second quarter and first half 2013Oslo, Norway, 22 August 2013: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, today announces its results for the second quarter and first half 2013.22 Aug 2013
